Holo-TC study results could boost B12 assay market
This article was originally published in Clinica
Executive Summary
Axis-Shield (Dundee, UK) has restated its belief that its Holo-TC assay for the biologically active part of the vitamin B12 molecule could replace serum B12 as a standard marker for Alzheimer's disease. The statement follows the completion of a joint study between the Universities of Oxford (UK) and Bergen (Norway), which confirmed that low serum levels of Holo-TC are associated with the disease.